Clinigen Group plc has signed an exclusive agreement with Lukare Medical to manage the supply and distribution of Elliotts Solution. Under the terms of this supply and distribution agreement with Lukare, Clinigen will provide physicians and pharmacists with access to Elliotts B Solution on an unlicensed, on-demand basis for patients around the world, excluding the US and Canada.
Marketing authorization is granted in the United States, but Elliotts B Solution is currently unavailable to meet patient needs elsewhere in the world. Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) is a diluent for methotrexate sodium, a chemotherapeutic drug and immune system suppressant, and cytarabine, a chemotherapeutic drug. These products require intrathecal administration (into the cerebrospinal fluid) for the prevention or treatment of meningeal leukaemia or lymphocytic lymphoma. About Elliotts B Solution
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.
The efficacy of Elliotts B Solution as a diluent for the intrathecal administration of chemotherapeutics is based on its ability to act as a buffer and to raise the pH of chemotherapeutics at acid pH (e.g. cytarabine) and to lower the pH of chemotherapeutics at...